LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Legend Biotech Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026
$18.65+0.17 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $7.23B
- P/E (TTM)
- –
- Dividend yield
- –
Legend Biotech Corp revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue |
|---|---|---|---|---|---|
| United States | $53.62M | $60.49M | $138.32M | $144.34M | 5.9% |
| China | $20.16M | $20.17M | $269.00K | $320.00K | 2.2% |
From the segment and revenue-disaggregation notes of Legend Biotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.